Investegate announcements from Galapagos NV, Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints
Investegate announcements from Galapagos NV, Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission